HLS Therapeutics (HLS) investor relations material

Business and financial profile

• North American specialty pharma portfolio spans neuro/psychiatric disorders and cardiovascular disease, using a model of acquiring US and Canadian commercialization rights.

• 2025 revenue was US$55.5M and adjusted EBITDA US$19.6M; 2026 guidance is US$56–60M revenue and US$18.5–21M adjusted EBITDA.

• Market capitalization was C$120M at Sept. 25, 2026.

Cardiovascular portfolio and growth

• Portfolio includes in-market Vascepa and NILEMDO, plus Nexlizet filed with Health Canada; NILEMDO launched in March 2026 and Nexlizet combines bempedoic acid with ezetimibe.

• Vascepa YTD 2026 units rose 17% and net sales rose 16% vs. YTD 2025; patent protection extends through the late 2030s, with operating margin expanding.

• NILEMDO launch showed growing demand; ~80% of eligible privately insured patients had reimbursement, and CDA-AMC issued a unanimous public-plan reimbursement recommendation; listings expected H1 2027.

• Nexlizet is targeted for a Health Canada decision by year-end 2026 and launch in H1 2027, subject to approval; observed LDL-C reduction is ~38% in markets where approved.

• The NILEMDO/Nexlizet opportunity illustration estimates C$50–100M revenue at 10–20% market penetration, based on net pricing and patient-compliance assumptions.

Clozaril and psychiatric portfolio

• Clozaril generated $27M in 2025 brand contribution, described as stable cash flow; branded share was ~50% of Canada’s clozapine market.

• An estimated ~1M Americans and Canadians live with treatment-resistant schizophrenia, with 1 in 4 patients currently on clozapine; clozapine is the only approved treatment for TRS.

• CSAN provides nurse educators, clinical coordinators and physician consultants; compliance was 32% higher than with the leading generic, alongside point-of-care WBC testing and therapeutic drug monitoring offerings.